R&D The future of drug development: Integrating open source and ... Clinical trials for drug development are becoming increasingly complex, with numerous variables that must be identified and defined from the start.
News Lundbeck planning for four novel drugs in phase 3 in 2026 Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.